ロード中...
Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
Subcutaneous (SC) trastuzumab has long been approved as a cancer treatment for early and advanced HER2-positive (HER2+) breast cancer by both the European Medicines Agency (EMA) and Agência Nacional de Vigilância Sanitária (ANVISA), the Brazilian National Health Surveillance Agency. A pivotal non-in...
保存先:
| 出版年: | Pharmaceut Med |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6182492/ https://ncbi.nlm.nih.gov/pubmed/30363808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40290-018-0247-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|